• Home
  •  / 4D Molecular Therapeutics

4D Molecular Therapeutics

OverviewSuggest Edit

4D Molecular Therapeutics is a biotechnology company focused on the creation of gene therapy products to cure genetic diseases. Its Therapeutic Vector Evolution platform enables to create adeno-associated virus (AAV) gene therapy vectors, which deliver genes to any diseased tissue or organ in the body.
TypePrivate
Founded2013
HQEmeryville, USMap
Website4dmoleculartherapeutics.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Nov 2020)88(+2%)
Revenue (FY, 2018)$14.1 M(+145%)
Cybersecurity ratingAMore

Key People/Management at 4D Molecular Therapeutics

David Kirn

David Kirn

Chief Executive Officer, Co-Founder, President & Director
John F. Milligan

John F. Milligan

Executive Chairman
David Schaffer

David Schaffer

Co-Founder, Chief Scientific Advisor & Director
August Moretti

August Moretti

Chief Financial Officer
Robert Fishman

Robert Fishman

Chief Medical Officer
Jacob Chacko

Jacob Chacko

Director
Show more

4D Molecular Therapeutics Office Locations

4D Molecular Therapeutics has an office in Emeryville
Emeryville, US (HQ)
5858 Horton St #455
Show all (1)

4D Molecular Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

4D Molecular Therapeutics total Funding

$100 m

4D Molecular Therapeutics latest funding size

$90 m

Time since last funding

2 years ago

4D Molecular Therapeutics investors

Viking Global Investors, Pfizer Venture Investments, Perceptive Advisors, Cystic Fibrosis Foundation, Chiesi Ventures, ArrowMark Partners, Pappas Capital, Ridgeback Capital, CureDuchenne Ventures, Janus Henderson Investors, Mirae Asset Global Investments, Berkeley Catalyst Fund (BCF)
4D Molecular Therapeutics's latest funding round in September 2018 was reported to be $90 m. In total, 4D Molecular Therapeutics has raised $100 m
Show all financial metrics

4D Molecular Therapeutics Revenue

4D Molecular Therapeutics's revenue was reported to be $14.13 m in FY, 2018 which is a 144% increase from the previous period.
USD

Revenue (FY, 2018)

14.1m

Revenue growth (FY, 2017 - FY, 2018), %

144%

Net income (FY, 2018)

(9.6m)

EBIT (FY, 2018)

(10.4m)

Cash (30-Jun-2019)

72.9m
USDFY, 2017FY, 2018

Revenue

5.8m14.1m

Revenue growth, %

144%

General and administrative expense

3.5m6.2m

R&D expense

13.6m18.4m
show all
Annual
USDFY, 2017FY, 2018

Cash

23.9m91.8m

Accounts Receivable

321.0k1.1m

Current Assets

24.5m94.1m

PP&E

2.7m2.5m
Quarterly
USDQ2, 2019

Cash

72.9m

Accounts Receivable

1.2m

Current Assets

75.4m

PP&E

4.0m
show all
Annual
USDFY, 2017FY, 2018

Net Income

(11.2m)(9.6m)

Depreciation and Amortization

626.0k697.0k

Accounts Payable

(114.0k)438.0k

Cash From Operating Activities

8.2m(16.3m)
Quarterly
USDQ2, 2018Q2, 2019

Net Income

(5.2m)(16.5m)

Depreciation and Amortization

341.0k406.0k

Accounts Payable

559.0k62.0k

Cash From Operating Activities

(6.4m)(17.2m)
show all
USDFY, 2017

Financial Leverage

-1.4 x
Show all financial metrics

4D Molecular Therapeutics Operating Metrics

Oct, 2019

Drugs in Development

6

Industry Partners

2

Patents (US)

1

Pre-Clinical Phase Products

6
Show all operating metrics

4D Molecular Therapeutics Revenue Breakdown

Embed Graph

4D Molecular Therapeutics revenue breakdown by business segment: 63.6% from Collaboration and Research Revenue (Related Parties) and 36.4% from Collaboration and Research Revenue

4D Molecular Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about our premium products
SecurityScorecard logo

4D Molecular Therapeutics Online and Social Media Presence

4D Molecular Therapeutics's Trends

Embed Graph

4D Molecular Therapeutics Blogs

November 18, 2020

4D Molecular Therapeutics Appoints Nancy Miller-Rich and Shawn Tomasello to its Board of Directors

Emeryville, CA – November 18, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Nancy Miller-Rich and Shawn Tomasello to the Board of Directors. Nancy Miller-Rich brings …

 4D Molecular Therapeutics Frequently Asked Questions

  • When was 4D Molecular Therapeutics founded?

    4D Molecular Therapeutics was founded in 2013.

  • Who are 4D Molecular Therapeutics key executives?

    4D Molecular Therapeutics's key executives are David Kirn, John F. Milligan and David Schaffer.

  • How many employees does 4D Molecular Therapeutics have?

    4D Molecular Therapeutics has 88 employees.

  • What is 4D Molecular Therapeutics revenue?

    Latest 4D Molecular Therapeutics annual revenue is $14.1 m.

  • What is 4D Molecular Therapeutics revenue per employee?

    Latest 4D Molecular Therapeutics revenue per employee is $160.6 k.

  • Who are 4D Molecular Therapeutics competitors?

    Competitors of 4D Molecular Therapeutics include Intellia Therapeutics, Nzomics Biocatalysis and NTrans Technologies.

  • Where is 4D Molecular Therapeutics headquarters?

    4D Molecular Therapeutics headquarters is located at 5858 Horton St #455, Emeryville.

  • Where are 4D Molecular Therapeutics offices?

    4D Molecular Therapeutics has an office in Emeryville.

  • How many offices does 4D Molecular Therapeutics have?

    4D Molecular Therapeutics has 1 office.